论文部分内容阅读
小鼠腹腔接种1×10~5个小鼠肉瘤S180或恶性淋巴瘤(ARS)瘤细胞后,腹腔注射SpA菌体,可获得明显的免疫治疗效果。注射SpA菌体时间越接近瘤细胞接种日期,免疫治疗效果越好,对S180和ARS的保护率可分别达44.5—55.4％和62.5—80％,相反,给SpA菌体的时间越晚,治疗效果越差,这表明SpA菌体的免疫治疗效果与瘤细胞增殖数量有关。根据实验结果,对SpA菌体作为免疫调整剂用于肿瘤治疗的可能性进行了讨论。
After mice were intraperitoneally inoculated with 1×10~5 mouse sarcoma S180 or malignant lymphoma (ARS) tumor cells, intraperitoneal injection of SpA cells resulted in obvious immunotherapy effects. The closer the injection time of SpA cells to the date of inoculation of tumor cells, the better the immunotherapy effect. The protection rates for S180 and ARS can reach 44.5-55.4% and 62.5-80%, respectively. On the contrary, the time for SpA cells is later, the treatment The worse the effect, this indicates that the immunotherapy effect of SpA cells is related to the number of tumor cell proliferation. Based on the experimental results, the possibility of using SpA as an immunomodulator for tumor treatment was discussed.